Global Albumin Market- By Type (Human Serum Albumin, Recombinant Albumin, and Bovine Serum), By Application (Therapeutics, Component of Media, Drug Formulation & Vaccines, and Other Applications), By End-User (Pharmaceutical & Biotechnology Industry, Hospital & Clinics, and Research Institutes), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Global Albumin Market size reached USD 5,352 Mn in 2022, to reach USD 9,799 Mn by 2032, exhibiting a (CAGR) of 6.4% during 2023-2032

Plasma from the blood contains albumin, the most abundant protein. It is used therapeutically to replace fluids that have been lost and to help restore blood volume after injuries, infections, surgeries, burns, and liver diseases. Reducing aggregation, surface absorption, and oxidation helps drugs stay in place. Serum albumin of various types is frequently used in clinical settings. Bovine plasma and human plasma are the sources of bovine serum albumin and human serum albumin, respectively.

Albumin is a protein abundant in blood and necessary for controlling the blood’s osmotic pressure. Its chemical and physical properties have been used in several ways by pharmaceutical companies. Manufacturing facilities have been established in various nations to investigate better and comprehend the product’s numerous applications.

Furthermore, integrating nanotechnology and recombinant DNA technology has created new possibilities for the biotechnology industries through increased protein use. As a result, businesses are making significant investments in the market. Additionally, the albumin market’s expansion has been fueled by the advancement of novel drugs that have increased sales due to their therapeutic potential against hypoalbuminemia.

The development of new albumin products by several key players and an increase in the prevalence of life-threatening disorders, cardiac surgeries, infections, and particular liver diseases that result in hypoalbuminemia are significant contributors to the expansion of the global albumin market.

Furthermore, an increase in the production of immunoglobulins and plasma collection, the development of plant-based albumin, and an increase in the demand for albumin in R&D activities are all drivers of the albumin market’s expansion. In addition, the market is expected to expand because more surgeries for cancer can cause hypoalbuminemia.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Albumin Is an Innovative Protein with Multiple Applications: Albumin is an integral protein found in blood plasma that plays an indispensable role in medical and biotechnological applications, serving both therapeutically and as an important diagnostic and research component.
• Clinical Application in Fluid Replacement Therapy: Human serum albumin can be utilized as part of fluid replacement therapy in critically ill patients with hypoalbuminemia to assist with oncotic pressure management, prevent edema formation and enhance patient outcomes.
• Albumin’s Stable Demand in Pharmaceutical Formulations: Albumin is an integral component in numerous pharmaceutical formulations, from vaccines and certain medications, to drug delivery systems that promote drug stability and efficacy. It plays an integral part in keeping pharmaceutical formulations stable.
• Applications in Diagnostics and Research: Albumin is used extensively for diagnostic testing and research. It serves as a stabilization agent for enzymes and antibodies, making various assays and experiments possible within life sciences research.

Type Analysis

Human Serum Albumin Dominated the Market.

Due to a rise in demand for drug development, an increase in pharmaceutical R&D activities, and a surge in the adoption of albumin products, the human serum albumin segment dominated the market and is anticipated to continue doing so during the forecast period.

However, the recombinant albumin market is expected to expand significantly over the forecast period due to a rise in the number of key players involved in albumin development and an increase in the number of surgeries performed due to hypoalbuminemia.

Application Analysis

The Therapeutics Sector is Anticipated to Lead the Market During the Forecast Period.

Due to an increase in the demand for albumin in drug discovery, an increase in the number of cardiac disorders, and an increase in the prevalence of trauma and burns cases, the therapeutics sector is anticipated to maintain its lead throughout the forecast period. In addition, due to an increase in cancer cases, vaccines & drug formulations are expected to grow significantly over the forecast period.

End-User Analysis

Higher Demand from Hospitals & Clinics for Therapeutic Applications Results in the Hospitals & Clinics Sector Dominance.

In hospitals and clinics, the number of prescriptions for drugs to treat associated diseases has increased. Additionally, the prevalence of drugs in hospitals has grown due to hypoalbuminemia-related hospital admissions, resulting in the sector’s dominance. During the forecast period, the pharmaceutical and biotechnology industries will expand due to the increasing use of albumin in creating new therapeutic solutions.

Therefore, the pharmaceutical and biotechnology sector is anticipated to experience the highest CAGR during the forecast period. However, research institute demand for BSA is expected to grow comparatively faster during the forecast period due to its stable nature as a protein standard.

Key Market Segments

Based on Type

• Human Serum Albumin
• Recombinant Albumin
• Bovine Serum

Based on Application

• Therapeutics
• Component of Media
• Drug Formulation & Vaccines
• Other Applications

Based on End-User

• Pharmaceutical & Biotechnology Industry
• Hospital & Clinics
• Research Institutes

Drivers

In Drug Delivery Increasing Use of Recombinant Albumin is likely to lead to Market Growth

Recombinant DNA technology has made significant contributions to human life in recent years. In the laboratory, recombinant techniques can safely produce essential components such asproteins. Recombinant DNA technology has demonstrated its value in this market as well because it is a technology that can be used in a variety of fields.

Manufacturers typically choose recombinant albumin to research and develop novel medications to treat hypoalbuminemia, hypovolemia, and other conditions. The product captures the R&D market because it protects the serum’s biological, immunological, and biochemical properties. For instance, Novartis partnered with the UK-based recombinant human albumin manufacturer Albumedix. Novartis was permitted by this agreement to investigate Albudemix’s platform for the creation of several targets and therapies for drug delivery applications.

Restraints

Product Adoption is Restricted in Emerging Nations by Strict Government Regulations.

Although hypovolemia and hypoalbuminemia are becoming more common worldwide, the use of albumin is constrained by a lack of therapeutic products and stringent government regulations. Stringent government regulations governing the production of therapeutic products are the main factors preventing the market from expanding.

For instance, the United States government ensures that the distributed and collected plasma meets international safety, quality, and potency standards. In addition, the issue that currently confronts the market is the absence of medications that can treat disorders. Therefore, the abovementioned factors will restrain the market growth during the forecast period.

Trends

Nanoparticles Based On Albumin for Drug Delivery to Boost Growth

Nanotechnology is increasingly being used to create new methods in today’s biotechnology and pharmaceutical industries. As a result, the industry’s major players are using this technology to improve drug delivery methods. Additionally, nanoparticle-based systems are demonstrating their viability as nanomedicine’s clinical excipients. Albumin is a basic template that is a nano-carrier for drug delivery thanks to advantages like its excellent half-life and lyoprotective properties.

Furthermore, because they are biocompatible, non-toxic, and biodegradable, albumin-based nanoparticles are the best materials for nanotechnology-based drug delivery. These advantages are advantageous for drug delivery and manufacturers’ advancement in novel drugs. As a result, the market’s expansion during the forecast period is likely to be driven by their integration with nanotechnology.

Regional Analysis

Asia- Pacific Dominates the Global Albumin Market During the Forecast Period.

The Asia-Pacific region accounted for the highest revenue of 38% in the global market. The high drug sales and the enhancement of plasma fractionation services in China are the factors that characterize the market in the region. China’s dominance is primarily attributable to rising consumption. Due to the expensive product prices, China has become the largest market, surpassing other nations.

In addition, the enhancement of manufacturing units, the widespread use of drugs, and rising investments in R&D in the region are all expected to drive growth in Asia-Pacific during the forecast period. During the forecast period, a lower CAGR is anticipated for North America and Europe markets. However, North America’s market is anticipated to expand steadily due to the region’s advanced healthcare facilities and drug supply.

The Middle East and Africa markets are still in their infancy. Still, it is expected to expand significantly during the forecast period due to the penetration of plasma fractionation facilities to encourage albumin production and initiate additional R&D.

However; market demand is anticipated to be fueled during the forecast period by the rising incidence of hypovolemia and the diseases associated with it and the expansion of healthcare infrastructure in these regions.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

To Maintain its Leadership position, CSL Limited Employs an Acquisition Strategy.

The global market is highly concentrated, and several significant players dominate and produce advanced goods. With an estimated 30% of the global market, CSL Limited is one of the leading businesses. CSL’s expansion of its commercial footprint throughout China due to its acquisition of Chinese market players has resulted in a greater volume of drug sales.

Takeda, S.A., Grifols, and others are also making significant investments in research and development to increase the market’s potential. Furthermore, during the forecast period, the market expansion is anticipated to be fueled by ongoing investments in R&D facilities and fractionation units. This is expected to positively affect the market because these businesses are expected to increase their share of the global albumin market over the forecast period.

A few key companies in the market are Octapharma AG, Biotest AG, Baxter International Inc., Grifols, S.A., Thermo Fisher Scientific, Ventria Bioscience Inc., Albumedix Ltd., HiMedia Laboratories, Sigma-Aldrich Co., China Biologic Products Inc., Merck KGaA, HiMedia Laboratories Pvt. Ltd., Aadi Bioscience, Inc., Medxbio Pte Ltd, Thermo Fisher Scientific Inc., Grifols SA, and other major companies.

Market Key Players

• CSL Limited
• Octapharma AG
• Grifols, S.A
• Kedrion S.p.A
• Merck KGaA
• Novozymes
• Biotest AG
• Bristol-Myers Squibb Company
• Other Key Players.

Key Industry developments

• In July 2021- As part of its expansion strategy, Grifols and ImmunoTek agreed to open 21 plasma centers. Sales, innovation, and the market would all benefit from this.
• In March 2021- Aledix partnered with FUJIFILM Wako Pure Chemical Corporation to supply recombinant human albumin to the Chinese and Japanese markets. The partnership strengthens Albumedix’s commitment to regional biopharmaceutical and advanced therapy developers.
• In February 2021- Kamada Ltd. purchased the plasma collection center from the Beaumont, Texas-based privately held Blood and Plasma Research, Inc. (B&PR), along with several related assets and rights. The Anti-D immunoglobulin collection facility at B&PR focuses primarily on collecting hyperimmune plasma.

Report Scope